RESUMEN
OBJECTIVE: To determine whether treatment with tumor necrosis factor alpha (TNFalpha)-blocking agents alters the incidence of new-onset uveitis in patients with juvenile idiopathic arthritis (JIA). STUDY DESIGN: Cohort study based on retrospective chart review. The charts of all 1109 patients with a diagnosis of JIA seen between January 1, 1996, and June 30, 2003, at our clinic were reviewed for diagnosis of uveitis and treatment with TNFalpha inhibitors. Cox regression analysis was performed with anti-TNFalpha treatment as a time-dependent covariate for risk of development of uveitis. RESULTS: We identified 70 patients treated with anti-TNFalpha without a prior diagnosis of uveitis. Two of these 70 patients (2.9%), both treated with etanercept, had development of new-onset uveitis during anti-TNFalpha therapy. One had juvenile psoriatic arthritis diagnosed 4.1 years before onset of uveitis. The other had extended oligoarticular JIA diagnosed 6.4 years before onset of uveitis. We found no statistically significant difference in the risk for development of uveitis between patients with or without anti-TNFalpha treatment. CONCLUSIONS: In our patients with JIA, anti-TNFalpha treatment did not alter the risk for development of new-onset uveitis. However, anti-TNFalpha therapy with etanercept did not prevent the development of uveitis in 2 patients.
Asunto(s)
Anticuerpos Monoclonales/efectos adversos , Artritis Juvenil/tratamiento farmacológico , Inmunoglobulina G/efectos adversos , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Uveítis/inducido químicamente , Uveítis/epidemiología , Adolescente , Niño , Preescolar , Estudios de Cohortes , Etanercept , Femenino , Humanos , Incidencia , Lactante , Infliximab , Masculino , Receptores del Factor de Necrosis Tumoral , Estudios Retrospectivos , Factores de RiesgoRESUMEN
Inflammatory linear verrucous epidermal nevus (ILVEN) is a rare, chronic skin condition that begins in early childhood. We present two children with ILVEN and arthritis, a previously undescribed association. We discuss the relevance of this association and suggest appropriate management for this arthritis.
Asunto(s)
Artritis/complicaciones , Nevo/complicaciones , Neoplasias Cutáneas/complicaciones , Antirreumáticos/uso terapéutico , Artritis/tratamiento farmacológico , Preescolar , Femenino , Humanos , Metotrexato/uso terapéutico , Resultado del TratamientoRESUMEN
We evaluated the self-esteem and quality of life of 47 children with morphea with the use of the Harter self-perception profile for children and Visual Analog Scale. Most children with morphea have normal self-worth and a high quality of life. Morphea, like some other childhood chronic illnesses, does not impair self-esteem.
Asunto(s)
Calidad de Vida , Esclerodermia Localizada/psicología , Autoimagen , Adolescente , Niño , Estudios Transversales , Femenino , Humanos , Masculino , Encuestas y CuestionariosRESUMEN
INTRODUCTION: Localized scleroderma (LS) can cause permanent disability, and there is no universally accepted effective treatment. Methotrexate (MTX) has been shown to be effective in the treatment of systemic sclerosis. OBJECTIVES: To determine the efficacy and tolerability of MTX and corticosteroid therapy in patients with LS. METHODS: MTX, 0.3 to 0.6 mg/kg per week, was given to 10 patients (6 girls, 4 boys; mean age, 6.8 years; mean disease duration before starting treatment, 4 years) with active LS. In addition, pulse intravenous methylprednisolone, 30 mg/kg for 3 days monthly for 3 months, was given to 9 patients at the initiation of therapy. RESULTS: One patient discontinued taking MTX after a month; the remaining 9 patients responded. The median time to response was 3 months (95% CI, 1.15-4.85). One responder discontinued taking MTX after a year because of leukopenia; the LS worsened within 2 months. In another patient LS flared up after 10 months and responded to an increased dose of MTX and intravenous methylprednisolone. At the last follow-up visit, all patients who continued to receive MTX therapy had inactive skin lesions. CONCLUSION: Treatment with MTX and corticosteroids appears to be effective in the treatment of LS and is generally well tolerated. A placebo-controlled study is necessary to confirm the efficacy of MTX therapy in LS.
Asunto(s)
Antiinflamatorios/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Glucocorticoides/uso terapéutico , Inmunosupresores/uso terapéutico , Metotrexato/uso terapéutico , Metilprednisolona/uso terapéutico , Esclerodermia Localizada/tratamiento farmacológico , Administración Oral , Antiinflamatorios/administración & dosificación , Niño , Preescolar , Intervalos de Confianza , Fármacos Dermatológicos/administración & dosificación , Fármacos Dermatológicos/efectos adversos , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Glucocorticoides/administración & dosificación , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/efectos adversos , Inyecciones Intravenosas , Leucopenia/inducido químicamente , Masculino , Metotrexato/administración & dosificación , Metotrexato/efectos adversos , Metilprednisolona/administración & dosificación , Placebos , Recurrencia , Inducción de RemisiónRESUMEN
OBJECTIVES: To determine the prevalence of abnormalities in myocardial perfusion or function in children with systemic lupus erythematosus (SLE), and describe potential factors that may predict their development. STUDY DESIGN: Patients (n = 40; 30 female) were enrolled through the Lupus Clinic at The Hospital for Sick Children between 1990 and 1992. Resting and exercise thallium myocardial perfusion scans, radionuclide angiography with multiple gated acquisition (MUGA), and resting M-mode and two-dimensional echocardiography were performed. RESULTS: All patients were free of symptoms, and none had a history of ischemic heart disease. Their median age was 15.9 years (range 10.5 to 19.8 years) at enrollment. Abnormalities of coronary perfusion were found in 5 (16%) of 31 patients (95% confidence interval: 3%, 29%) and included a large fixed perfusion defect in 1; 5 of 27 MUGA scans showed marginally low left ventricular ejection fractions at rest, whereas all had normal exercise responses. In the group with abnormal thallium scans, three of five patients had antiphospholipid antibodies detected, and two of four had an abnormal plasma lipid profile. This group tended to have a shorter disease duration and had received a lower cumulative dose of corticosteroids; these differences were not statistically significant compared with the group with normal scans. CONCLUSION: Asymptomatic abnormalities of myocardial perfusion occur in children with SLE and are more common than previously suspected. Patients with these abnormalities of myocardial perfusion may be predisposed to the previously recognized early-onset ischemic heart disease seen in adults with SLE.
Asunto(s)
Corazón/diagnóstico por imagen , Lupus Eritematoso Sistémico/fisiopatología , Isquemia Miocárdica/etiología , Adolescente , Antiinflamatorios/uso terapéutico , Anticuerpos Antifosfolípidos/sangre , Niño , Ecocardiografía , Prueba de Esfuerzo , Femenino , Glucocorticoides/uso terapéutico , Pruebas de Función Cardíaca , Humanos , Lípidos/sangre , Lupus Eritematoso Sistémico/tratamiento farmacológico , Masculino , Isquemia Miocárdica/diagnóstico , Angiografía por Radionúclidos , Esteroides , Tomografía Computarizada de Emisión de Fotón Único , Función VentricularRESUMEN
OBJECTIVE: This study was undertaken to investigate the recent finding of a seasonal difference in the onset of systemic-onset juvenile rheumatoid arthritis (SoJRA). We hypothesized that a seasonal onset pattern might implicate on infectious agent as a cause of SoJRA. METHODS: The date of onset was collected from the records of all patients with SoJRA from 1980 to 1992 at presentation to pediatric rheumatology clinics across Canada. The onset pattern of SoJRA was then compared with incidence data on viral infections obtained for the same period. RESULTS: Across Canada the onset of SoJRA was constant across the seasons. However, in the Prairie region there was a statistically significant seasonal pattern, with peaks in autumn and early spring. We could find no evidence that viral incidence correlated with disease incidence either throughout Canada or in the Prairie region. CONCLUSIONS: If a seasonal infectious agent causes SoJRA, then it is likely only one of several causes and may act only in certain regions. Future studies should be carried out in those areas where SoJRA does have a seasonal onset pattern.
Asunto(s)
Artritis Juvenil/epidemiología , Estaciones del Año , Adolescente , Edad de Inicio , Artritis Juvenil/virología , Canadá/epidemiología , Niño , Preescolar , Femenino , Humanos , Incidencia , Lactante , Recién Nacido , Masculino , Virosis/epidemiologíaRESUMEN
We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy. Although they had only a few nodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients. The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other. Physicians treating patients with methotrexate for juvenile rheumatoid arthritis must be aware of this extraarticular side effect.
Asunto(s)
Artritis Juvenil/tratamiento farmacológico , Metotrexato/efectos adversos , Nódulo Reumatoide/inducido químicamente , Adolescente , Femenino , Humanos , Hidroxicloroquina/uso terapéutico , Factor Reumatoide/sangre , Nódulo Reumatoide/tratamiento farmacológicoRESUMEN
We describe three cases of cerebral vein thrombosis (CVT) in girls with systemic lupus erythematosus. Severe, persistent, unremitting headache was a common manifestation. In the first patient, although the clinical features were suggestive of CVT, the diagnosis was delayed and she had a significant cerebral infarct. In the other two patients the diagnosis was made earlier and led to more rapid treatment; the institution of early therapy may have prevented further sequelae. The CVT was diagnosed in all patients with a combination of computed tomography and magnetic resonance imaging studies without the need for angiography. All patients were treated for their underlying systemic lupus erythematosus and with anticoagulation. All are receiving long-term low doses of warfarin and have not had any recurrences.
Asunto(s)
Embolia y Trombosis Intracraneal/etiología , Lupus Eritematoso Sistémico/complicaciones , Adolescente , Anticuerpos Antinucleares/sangre , Anticoagulantes/uso terapéutico , Niño , Femenino , Estudios de Seguimiento , Cefalea/etiología , Humanos , Embolia y Trombosis Intracraneal/sangre , Embolia y Trombosis Intracraneal/diagnóstico , Embolia y Trombosis Intracraneal/prevención & control , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/tratamiento farmacológico , Imagen por Resonancia Magnética , Factores de Tiempo , Tomografía Computarizada por Rayos XRESUMEN
Two unrelated patients with a family history of rheumatic fever had isolated, acquired chorea. Both index cases, as well as affected family members, had increased expression of the rheumatic B-cell alloantigen D8/17. This test may help differentiate Sydenham chorea from lupus chorea.
Asunto(s)
Linfocitos B/inmunología , Corea/diagnóstico , Isoantígenos , Fiebre Reumática/diagnóstico , Niño , Corea/etiología , Corea/genética , Diagnóstico Diferencial , Femenino , Humanos , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/genética , Masculino , Fiebre Reumática/complicaciones , Fiebre Reumática/genética , SíndromeRESUMEN
Eosinophilic synovitis occurred in a 7-year-old boy. Synovial fluid leukocytes were mostly eosinophils; the peripheral blood showed only mild eosinophilia. The level of eosinophil-derived neurotoxin in the synovial fluid was higher than that in the serum, suggesting intraarticular eosinophil degranulation. The IgE level was also elevated in the synovial fluid (3854 ng/ml) but normal in the serum (408 ng/ml), suggesting a localized immediate hypersensitivity immune response.
Asunto(s)
Eosinofilia/inmunología , Inmunoglobulina E/análisis , Ribonucleasas , Líquido Sinovial/inmunología , Sinovitis/inmunología , Niño , Neurotoxina Derivada del Eosinófilo , Eosinófilos/metabolismo , Eosinófilos/fisiología , Humanos , Inmunoglobulina E/sangre , Masculino , Neurotoxinas/análisis , Líquido Sinovial/química , Sinovitis/sangreRESUMEN
We retrospectively reviewed the charts and radiographs of 38 patients with systemic-onset juvenile rheumatoid arthritis, attempting to identify early in the disease course the clinical and laboratory observations most predictive of the later development of destructive arthritis. In 12 of the patients, destructive arthritis developed within 2 years of disease onset. When first examined, these patients could not readily be differentiated from those in whom joint destruction did not develop, but they more commonly had hepatosplenomegaly (p less than 0.04), serositis (p less than 0.01), and a lower mean serum albumin concentration (26.7 vs 31.3 gm/L; p less than 0.02). However, by 6 months after onset, patients with destructive arthritis more frequently had persistent systemic symptoms (92% vs 12%; p less than 0.0001), polyarthritis (67% vs 19%; p less than 0.0005), a lower mean hemoglobin level (95 vs 114 gm/L; p less than 0.001), a higher mean leukocyte count (21.2 vs 10 x 10(9)/L; p less than 0.0003), a higher mean platelet count (794 vs 400 x 10(9)/L; p less than 0.0001), and a higher mean erythrocyte sedimentation rate (43 vs 24 mm/hr; p less than 0.05). Multivariate analysis of the results at 6 months revealed that persistent systemic symptoms and a platelet count greater than or equal to 600 x 10(9)/L were the variables most highly predictive of the later development of joint destruction. We conclude that patients at high risk for the development of destructive arthritis may be identified within 6 months of disease onset, thereby indicating the need for more aggressive early therapy.
Asunto(s)
Artritis Juvenil/patología , Articulaciones/patología , Adolescente , Artritis Juvenil/diagnóstico por imagen , Artrografía , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Pronóstico , Estudios Retrospectivos , Factores de Riesgo , Factores de TiempoAsunto(s)
Lupus Eritematoso Sistémico/complicaciones , Tiroiditis Autoinmune/epidemiología , Autoanticuerpos/sangre , Niño , Femenino , Humanos , Lupus Eritematoso Sistémico/inmunología , Masculino , Prevalencia , Pruebas de Función de la Tiroides , Glándula Tiroides/inmunología , Tiroiditis Autoinmune/diagnóstico , Tiroiditis Autoinmune/inmunologíaRESUMEN
Because patients with Kawasaki disease have low serum concentrations of salicylates despite high doses, and because the free (unbound) drug is responsible for the pharmacologic effects of salicylates, we assessed salicylate protein binding in patients with Kawasaki disease. During the acute phase of the disease, protein binding of salicylate in 36 children with Kawasaki disease was 73 +/- 12%, significantly lower than during the subacute phase (90.4 +/- 8.7%; p less than 0.0005). Mean serum albumin concentration was 29.2 +/- 6.4 gm/L during the acute phase and 36.7 +/- 7.8 gm/L during the subsequent subacute phase (p less than 0.005). Salicylate protein binding was affected independently by both serum albumin and total salicylate levels. During the acute phase of Kawasaki disease, children had an average twofold increase in free salicylate compared with normoalbuminemic control subjects. A nomogram has been devised to derive free salicylate levels from the known total salicylate and serum albumin concentrations.
Asunto(s)
Síndrome Mucocutáneo Linfonodular/sangre , Salicilatos/sangre , Albúmina Sérica/metabolismo , Enfermedad Aguda , Adulto , Radioisótopos de Carbono , Niño , Humanos , Síndrome Mucocutáneo Linfonodular/tratamiento farmacológico , Unión Proteica , Salicilatos/administración & dosificación , Salicilatos/análisis , Albúmina Sérica/análisis , UltrafiltraciónAsunto(s)
Síndrome Mucocutáneo Linfonodular/sangre , Receptores de Interleucina-2/análisis , Enfermedad Aguda , Envejecimiento , Niño , Preescolar , Aneurisma Coronario/sangre , Aneurisma Coronario/etiología , Dilatación Patológica/sangre , Dilatación Patológica/etiología , Ecocardiografía , Femenino , Humanos , Lactante , Masculino , Síndrome Mucocutáneo Linfonodular/inmunología , SolubilidadRESUMEN
We report the cases of neonatal lupus erythematosus associated with significant hepatic involvement in three living infants and in one infant who died 3 hours after delivery. The three living infants had neonatal cholestasis as a major component of their clinical findings. Pathologic changes included giant cell transformation, ductal obstruction, and extramedullary hematopoiesis. Liver involvement has been noted incidentally in children with neonatal lupus erythematosus, but it has generally been attributed to hemodynamic compromise as a result of congenital heart block or systemic toxic reactions. We speculate that neonatal hepatitis proceeding to hepatic fibrosis may occur in neonatal lupus erythematosus, analogous to the occurrence of "idiopathic" congenital heart block. The neonatal hepatitis associated with neonatal lupus erythematosus is a form distinguishable from the "idiopathic" group. Liver involvement may be more common than was previously recognized, and prospective studies to look for maternal autoantibodies in idiopathic neonatal liver disease should be undertaken.
Asunto(s)
Hepatopatías/congénito , Lupus Eritematoso Sistémico/congénito , Anticuerpos Antinucleares/análisis , Femenino , Humanos , Recién Nacido , Hepatopatías/inmunología , Hepatopatías/patología , Lupus Eritematoso Sistémico/inmunología , Lupus Eritematoso Sistémico/patología , MasculinoRESUMEN
Tumor necrosis factor production by peripheral blood mononuclear cells was measured in 18 patients with Kawasaki disease. In patients studied during the acute febrile phase of their disease, there was increased spontaneous TNF production (mean 26.9 +/- 40.3 U/ml) compared with that of control subjects (1.0 +/- .86 U/ml) (p less than or equal to 0.025). Spontaneous TNF production by patients tested in the subacute or convalescent phase of the illness was significantly lower than that in patients tested during the acute illness (p less than or equal to 0.025). In all patients studied with serial acute and subacute-convalescent samples, TNF production was normal in the follow-up samples. Because TNF is a potent mediator of inflammation and causes damage to vascular endothelial cells, we suggest that TNF may be important in the pathogenesis of both the immune activation and endothelial cell damage characteristic of this illness.
Asunto(s)
Leucocitos Mononucleares/metabolismo , Síndrome Mucocutáneo Linfonodular/sangre , Factor de Necrosis Tumoral alfa/biosíntesis , Niño , Preescolar , Femenino , Humanos , Inmunización Pasiva , Lactante , Masculino , Síndrome Mucocutáneo Linfonodular/etiología , Síndrome Mucocutáneo Linfonodular/terapia , Factor de Necrosis Tumoral alfa/análisisRESUMEN
Twenty-seven patients with Raynaud syndrome (mean age at onset 11.7 years) were studied to determine the prevalence of primary Raynaud syndrome and to assess the predictive role of antinuclear antibody, nail-fold capillary microscopy, and photoelectric plethysmography in this population. Fourteen patients (52%) had a connective tissue disease, four (15%) had a probable connective tissue disease, and nine (33%) had primary Raynaud syndrome. In all patients with either a connective tissue disease or a probable connective tissue disease, there was a positive reaction to antinuclear antibody, in contrast to patients with primary Raynaud syndrome, in whom antinuclear antibody was not detected. Nail-fold capillary microscopy scores differed significantly between patients with either a connective tissue disease or a probable connective tissue disease and those with primary Raynaud syndrome for both enlarged loop score (p less than 0.025 and less than 0.05, respectively) and avascular score (p less than 0.005 and less than 0.01, respectively). Photoelectric plethysmography scores were reduced in all groups but did not differ significantly between groups. Our findings suggest that in children with Raynaud syndrome, the primary type is more common than was originally suspected, and that both antinuclear antibody and nail-fold capillary microscopy, but not photoelectric plethysmography, can distinguish patients with primary Raynaud syndrome from those with either a connective tissue disease or a probable connective tissue disease.
Asunto(s)
Enfermedad de Raynaud/epidemiología , Adolescente , Anticuerpos Antinucleares/análisis , Niño , Preescolar , Enfermedades del Tejido Conjuntivo/complicaciones , Enfermedades del Tejido Conjuntivo/diagnóstico , Diagnóstico Diferencial , Femenino , Humanos , Lactante , Masculino , Enfermedad de Raynaud/diagnóstico , Enfermedad de Raynaud/etiologíaRESUMEN
Eleven children with reflex neurovascular dystrophy were investigated by technetium-labeled methylene diphosphonate bone scanning. Eight of 12 scans demonstrated abnormal findings, four showing diffusely decreased uptake and four diffusely increased uptake of the radionuclide in the affected site. Three scans showed normal findings initially, as did one previously abnormal scan when repeated in the asymptomatic patient 6 months later. Diffusely abnormal findings can be helpful in the diagnosis of childhood reflex neurovascular dystrophy, but a normal scan does not exclude the diagnosis.